{"id":606816,"date":"2022-07-05T18:54:01","date_gmt":"2022-07-05T18:54:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=606816"},"modified":"2022-07-05T18:54:01","modified_gmt":"2022-07-05T18:54:01","slug":"bipolar-depression-pipeline-analysis-2022-current-therapies-emerging-drugs-clinical-trials-and-treatment-outlook-key-companies-otsuka-neurorx-lundbeck-celon-pharma-sunovion-and-others","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/bipolar-depression-pipeline-analysis-2022-current-therapies-emerging-drugs-clinical-trials-and-treatment-outlook-key-companies-otsuka-neurorx-lundbeck-celon-pharma-sunovion-and-others_606816.html","title":{"rendered":"Bipolar Depression Pipeline Analysis, 2022 &#8211; Current Therapies, Emerging Drugs, Clinical Trials, and Treatment Outlook | Key Companies &#8211;  Otsuka, NeuroRx, Lundbeck, Celon Pharma, Sunovion, and Others"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Bipolar Depression Pipeline Analysis, 2022 - Current Therapies, Emerging Drugs, Clinical Trials, and Treatment Outlook | Key Companies -  Otsuka, NeuroRx, Lundbeck, Celon Pharma, Sunovion, and Others\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Bipolar Depression Pipeline Analysis, 2022 - Current Therapies, Emerging Drugs, Clinical Trials, and Treatment Outlook | Key Companies -  Otsuka, NeuroRx, Lundbeck, Celon Pharma, Sunovion, and Others\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">\u201cBipolar Depression Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Bipolar Depression Market.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>Bipolar Depression Pipeline report<\/strong> embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report also covers a detailed description of the drug including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/25494bf9ecb2720ac7b697e327347fd9.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/bipolar-depression-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Bipolar Depression Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights about companies that are developing therapies for the <strong>treatment of Bipolar Depression<\/strong> with aggregate therapies developed by each company for the same.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Bipolar Depression Treatment.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Bipolar Depression key companies<\/strong> involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\"><strong>Bipolar Depression Drugs<\/strong> under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the <strong>Bipolar Depression market.<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bipolar-depression-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/bipolar-depression-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Bipolar Depression Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><em>As per DelveInsight&rsquo;s estimation, the treatment space will experience a significant impact due to the continuous effort by the companies actively engaged in the research and development activities.&nbsp;<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">The Bipolar Depression market size in the 7MM is expected to increase in the coming years owing to the launch of emerging therapies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key companies in the Bipolar Depression Market include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">NeuroRx<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Lundbeck<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Intra-Cellular Therapies<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Otsuka Pharmaceutical<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">COMPASS Pathways<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Celon Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Sunovion (Sumitomo Dainippon Pharma)<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And others.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Bipolar Depression Therapies Covered in the report include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">SEP-4199<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Caplyta (Lumateperone; ITI-007)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">NRX-100\/NRX-101<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Rexulti\/Rxulti (Brexpiprazole)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">COMP 360 (Psilocybin Therapy)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Falkieri (Esketamine DPI)<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The <strong>pipeline for Bipolar Depression<\/strong> brings a positive ray of hope for a better treatment pattern in the market in the upcoming years. The current scenario also anticipates a positive shift in the market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get More Detailed Insights Into the Emerging Therapies &amp; Key Companies &#8211;&nbsp; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bipolar-depression-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/bipolar-depression-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Bipolar Depression Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Bipolar Depression &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Bipolar Depression Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Bipolar Depression Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Bipolar Depression Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Bipolar Depression Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Bipolar Depression Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Key Companies in the Bipolar Depression Market<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Key Products in the Bipolar Depression Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Bipolar Depression Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Bipolar Depression Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Bipolar Depression Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF Report &#8211;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/bipolar-depression-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/bipolar-depression-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<br \/><\/strong>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Other Trending Healthcare Reports by DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/intracardiac-echocardiography-devices-market\">Intracardiac Echocardiography Devices Market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&ldquo;<strong>Intracardiac Echocardiography Devices Market<\/strong>&rdquo; report delivers an in-depth understanding of the historical and forecasted market trends for Intracardiac Echocardiography Devices. Additionally, it covers the ongoing development, collaboration, merger &amp; acquisitions, emerging products, and key companies operating in the market.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=bipolar-depression-pipeline-analysis-2022-current-therapies-emerging-drugs-clinical-trials-and-treatment-outlook-key-companies-otsuka-neurorx-lundbeck-celon-pharma-sunovion-and-others\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=bipolar-depression-pipeline-analysis-2022-current-therapies-emerging-drugs-clinical-trials-and-treatment-outlook-key-companies-otsuka-neurorx-lundbeck-celon-pharma-sunovion-and-others\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP \u201cBipolar Depression Pipeline Insight, 2022&#8243; report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Bipolar Depression Market. The Bipolar Depression Pipeline report embraces in-depth commercial and clinical assessment &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/bipolar-depression-pipeline-analysis-2022-current-therapies-emerging-drugs-clinical-trials-and-treatment-outlook-key-companies-otsuka-neurorx-lundbeck-celon-pharma-sunovion-and-others_606816.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[425,426,405,417,406],"tags":[],"class_list":["post-606816","post","type-post","status-publish","format-standard","hentry","category-Finance","category-Financial-Market","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/606816","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=606816"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/606816\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=606816"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=606816"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=606816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}